European Commission concludes talks for COVID-19 vaccine portfolio

European Commission concludes talks to expand COVID-19 vaccine portfolio
© iStock/AlexSava

The European Commission has recently concluded exploratory talks to purchase 225 million doses of a potential COVID-19 vaccine.

The European Commission talks with CureVac follow positive steps taken with Sanofi-GSK and Johnson & Johnson, and the signature of an Advanced Purchase Agreement for a potential COVID-19 vaccine with AstraZeneca. The new, envisioned contract would provide the possibility for all EU member states to purchase the vaccine, as well as to donate to lower and middle income countries or re-direct to European countries.

Protecting Europe against COVID-19

The vaccine is to be supplied once it been has proven to be safe and effective against COVID-19, and the Commission pursues intensive discussions with other vaccine manufacturers.

CureVac is a European company developing a new class of vaccines based on messenger RNA (mRNA), transported into cells by lipid nanoparticles. The vaccine platform has been developed over the last decade. The basic principle is the use of this molecule as a data carrier for information, which helps  the body to  produce its own active substances to combat various diseases.

Ursula von der Leyen, President of the European Commission, said: “The European Commission delivers on its promise to secure rapid access for Europeans and the world to a safe vaccine that protects us against the coronavirus. Each round of talks that we conclude with the pharmaceutical industry brings us closer to beating this virus. We will soon have an agreement with CureVac, the innovative European firm that received earlier EU funding to produce a vaccine in Europe. And our negotiations continue with other companies to find the technology that would protect us all.”

Stella Kyriakides, Commissioner for Health and Food Safety, said: “Today we concluded talks with the European company CureVac to increase the chances of finding an effective coronavirus vaccine. We continue to work shoulder to shoulder with Member States and with vaccine developers to fulfil the aims of our European Vaccines Strategy – a vaccine for all.”

The exploratory talks concluded today are intended to result in an Advance Purchase Agreement to be financed with the Emergency Support Instrument, which has funds dedicated to the creation of a portfolio of potential vaccines with different profiles, and produced by different companies.


Please enter your comment!
Please enter your name here